Hemophilia B

An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B
NCT06008938 | Observational

This observational, post-authorization, long-term follow-up study aims to investigate the short and long-term effectiveness and safety of HEMGENIX in patients with hemophilia B. The study will also include a cohort of patients with hemophilia B treated with FIX prophylaxis to enable interpretation of relevant efficacy and safety findings of HEMGENIX.

Trial Information
1 Sites
500 Participants
Recruiting
18 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

SUBMIT
American Thrombosis and Hemostasis Network
Rochester,New York,United States,14604

Study Eligibility Criteria

  • HEMGENIX Cohort:
  • Treatment with commercial HEMGENIX.
  • Have provided signed written informed consent within 3 months before or within 6 months after HEMGENIX treatment, or within 6 months of when the study is initiated at the participating site.
  • FIX Prophylaxis Cohort:
  • Adult patients (≥ 18 years) with hemophilia B who have consented and enrolled in ATHN Transcends Hemophilia Cohort (or a similar registry) and are receiving FIX prophylaxis therapy.
  • HEMGENIX Cohort:
  • The patient population that will be observed in this study must not have been treated with etranacogene dezaparvovec in a clinical trial.

Additional Studies

Additional studies can be found at ClinicalTrials.gov